Yaron Aviv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yaron Aviv has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Ran Kornowski
Rabin Medical Centre
7 shared publications - Arthur Shiyovich
Heart and Vascular Institute, Brigham and Women’s Hospital, Boston, MA 02115, USA
5 shared publications - Ashraf Hamdan
Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel
5 shared publications Ran Kornowski
Gray Faculty of Medical and Health Science, Tel Aviv University, Tel-Aviv, Israel; Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel
5 shared publications- Ygal Plakht
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 8410501, Israel
5 shared publications - Maya Wiessman
Internal Medicine Department, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX, USA
4 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (7) , 101596
RetiMap
- 18 June 2026
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 11 (7) , 101596
Open AccessRetiMap
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045425
Aortic Valve Calcium Score Spectrum Identifies Bimodal Outcomes for Transcatheter Aortic Valve Implantation: Insights From the AMTRAC Registry
Background: Degenerative calcification is the primary mechanism underlying severe aortic stenosis; however, some patients with hemodynamically severe aortic stenosis have low aortic valve calcium scores (AVCS), suggesting heterogeneous disease processes. This study aimed to evaluate the clinical characteristics and outcomes across the spectrum of AVCS. Methods: We performed a retrospective analysis of the AMTRAC (Aortic+Mitral Transcatheter Valve) registry, including 3766 patients with severe aortic stenosis who underwent transcatheter aortic valve implantation across 16 centers mainly in Europe (2013–2024). Patients were stratified into three groups of low, high, or very high based on their AVCS. The primary end point was 3‐year mortality. Secondary end points included periprocedural outcomes (Valve Academic Research Consortium‐3) and posttranscatheter aortic valve implantation hemodynamics. Results: Patients with low AVCS more frequently presented with low‐gradient aortic stenosis and advanced New York Heart Association classes. At 3 years, mortality displayed a bimodal pattern in association with AVCS spectrum: 30.5% in the low, 26.5% in the high, and 31.3% in the very‐high AVCS group ( P P P <0.05 for both). Conclusions: Low AVCS defines a unique phenotype marked by predominant fibrosis, advanced symptoms, and increased mortality despite fewer procedural complications. In contrast, very‐high AVCS is linked to higher procedural risk, more bicuspid valves, and increased mortality. These insights challenge calcification‐based criteria and support incorporating fibrosis assessment into treatment strategies.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045425
Open AccessAortic Valve Calcium Score Spectrum Identifies Bimodal Outcomes for Transcatheter Aortic Valve Implantation: Insights From the AMTRAC Registry
Background: Degenerative calcification is the primary mechanism underlying severe aortic stenosis; however, some patients with hemodynamically severe aortic stenosis have low aortic valve calcium scores (AVCS), suggesting heterogeneous disease processes. This study aimed to evaluate the clinical characteristics and outcomes across the spectrum of AVCS. Methods: We performed a retrospective analysis of the AMTRAC (Aortic+Mitral Transcatheter Valve) registry, including 3766 patients with severe aortic stenosis who underwent transcatheter aortic valve implantation across 16 centers mainly in Europe (2013–2024). Patients were stratified into three groups of low, high, or very high based on their AVCS. The primary end point was 3‐year mortality. Secondary end points included periprocedural outcomes (Valve Academic Research Consortium‐3) and posttranscatheter aortic valve implantation hemodynamics. Results: Patients with low AVCS more frequently presented with low‐gradient aortic stenosis and advanced New York Heart Association classes. At 3 years, mortality displayed a bimodal pattern in association with AVCS spectrum: 30.5% in the low, 26.5% in the high, and 31.3% in the very‐high AVCS group ( P P P <0.05 for both). Conclusions: Low AVCS defines a unique phenotype marked by predominant fibrosis, advanced symptoms, and increased mortality despite fewer procedural complications. In contrast, very‐high AVCS is linked to higher procedural risk, more bicuspid valves, and increased mortality. These insights challenge calcification‐based criteria and support incorporating fibrosis assessment into treatment strategies.
- Open Access
- 11 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Coronary atherosclerotic burden in patients with embolic stroke of undetermined source
Introduction: Embolic Stroke of Undetermined Source (ESUS) is a subtype of cryptogenic stroke with no clear etiology despite thorough evaluation. Atrial fibrillation (AF) is detected in only ~40% of cases, and trials of empiric anticoagulation have failed to reduce recurrence, suggesting other mechanisms such as subclinical atherosclerosis may contribute. Coronary artery calcium (CAC) scoring is a validated marker of atherosclerosis, yet its burden in ESUS remains underexplored. Patients and methods: We conducted a retrospective cohort study of consecutive ESUS patients admitted between April 2019 and December 2023 who underwent cardiac CT angiography (CCTA) during diagnostic work-up. CAC scores were calculated using the Agatston method, and percentiles were derived from the MESA database, adjusted for age, sex, and ethnicity. Patients with prior coronary interventions were excluded. Results: Among 165 ESUS patients (median age 73.0 [IQR 66.5–82.0]; 47.9% female), the median CAC score was 225 [IQR 41.5–623.5] AU, and the median CAC percentile was 65 [IQR 40.05–85.0], significantly higher than population norms (p < 0.001). Patients ⩽65 years had higher CAC percentiles than older patients (80.0 [58.2–90.7] vs 61.0 [36.0–80.0], p = 0.002), despite similar CAC scores (p = 0.396). Conclusion: ESUS patients exhibit a high burden of coronary atherosclerosis, particularly notable in younger individuals. Elevated CAC may reflect both subclinical atherosclerosis and a broader cardiovascular risk profile, offering insight into stroke pathophysiology and the limited efficacy of empiric anticoagulation. CAC assessment could improve etiologic classification and inform tailored secondary prevention.
- 11 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 11 (1)
Open AccessCoronary atherosclerotic burden in patients with embolic stroke of undetermined source
Introduction: Embolic Stroke of Undetermined Source (ESUS) is a subtype of cryptogenic stroke with no clear etiology despite thorough evaluation. Atrial fibrillation (AF) is detected in only ~40% of cases, and trials of empiric anticoagulation have failed to reduce recurrence, suggesting other mechanisms such as subclinical atherosclerosis may contribute. Coronary artery calcium (CAC) scoring is a validated marker of atherosclerosis, yet its burden in ESUS remains underexplored. Patients and methods: We conducted a retrospective cohort study of consecutive ESUS patients admitted between April 2019 and December 2023 who underwent cardiac CT angiography (CCTA) during diagnostic work-up. CAC scores were calculated using the Agatston method, and percentiles were derived from the MESA database, adjusted for age, sex, and ethnicity. Patients with prior coronary interventions were excluded. Results: Among 165 ESUS patients (median age 73.0 [IQR 66.5–82.0]; 47.9% female), the median CAC score was 225 [IQR 41.5–623.5] AU, and the median CAC percentile was 65 [IQR 40.05–85.0], significantly higher than population norms (p < 0.001). Patients ⩽65 years had higher CAC percentiles than older patients (80.0 [58.2–90.7] vs 61.0 [36.0–80.0], p = 0.002), despite similar CAC scores (p = 0.396). Conclusion: ESUS patients exhibit a high burden of coronary atherosclerosis, particularly notable in younger individuals. Elevated CAC may reflect both subclinical atherosclerosis and a broader cardiovascular risk profile, offering insight into stroke pathophysiology and the limited efficacy of empiric anticoagulation. CAC assessment could improve etiologic classification and inform tailored secondary prevention.
- Open Access
- 10 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8754
Effects of Contrast Media on Renal Function Following Computed Tomography Prior to Transcatheter Aortic Valve Implantation
Background: Preprocedural contrast-enhanced computed tomography (CT) is essential for planning Transcatheter Aortic Valve Implantation (TAVI), but concerns remain regarding contrast-induced (CI) acute kidney injury, especially in patients with chronic kidney disease. This study aimed to evaluate the incidence of CI-acute kidney injury following contrast-enhanced CT performed before TAVI. Methods: CI-acute kidney injury was defined according to the Kidney Disease—Improving Global Outcomes (KDIGO) guidelines. Nonionic, low-osmolality iodinated contrast material was used for all CT studies. The primary outcome was the incidence of CI-acute kidney injury post-CT. Secondary outcomes included the need for renal replacement therapy and the 30-day post-CT mortality rate. Results: Our study included 359 patients. The median age was 81, and 44% were males. Chronic kidney disease was present in 59.3% of patients, and the overall incidence of CI-acute kidney injury occurred in 24 patients (7%), without a significant difference between patients with and without baseline chronic kidney disease (4.8% vs. 8%, respectively; p = 0.331). Three consecutive creatinine tests within a median of 5.8 days showed that acute kidney injury occurred in only six patients (1.7%). No patients required new dialysis initiation within 30 days. Multivariable analysis did not identify baseline chronic kidney disease or IV contrast volume as independent predictors of CI-acute kidney injury. Conclusions: CI-acute kidney injury following pre-TAVI CT is low, even among patients with chronic kidney disease. Most cases were transient and did not require dialysis. Routine avoidance of CT due to chronic kidney disease may not be warranted.
- 10 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8754
Open AccessEffects of Contrast Media on Renal Function Following Computed Tomography Prior to Transcatheter Aortic Valve Implantation
Background: Preprocedural contrast-enhanced computed tomography (CT) is essential for planning Transcatheter Aortic Valve Implantation (TAVI), but concerns remain regarding contrast-induced (CI) acute kidney injury, especially in patients with chronic kidney disease. This study aimed to evaluate the incidence of CI-acute kidney injury following contrast-enhanced CT performed before TAVI. Methods: CI-acute kidney injury was defined according to the Kidney Disease—Improving Global Outcomes (KDIGO) guidelines. Nonionic, low-osmolality iodinated contrast material was used for all CT studies. The primary outcome was the incidence of CI-acute kidney injury post-CT. Secondary outcomes included the need for renal replacement therapy and the 30-day post-CT mortality rate. Results: Our study included 359 patients. The median age was 81, and 44% were males. Chronic kidney disease was present in 59.3% of patients, and the overall incidence of CI-acute kidney injury occurred in 24 patients (7%), without a significant difference between patients with and without baseline chronic kidney disease (4.8% vs. 8%, respectively; p = 0.331). Three consecutive creatinine tests within a median of 5.8 days showed that acute kidney injury occurred in only six patients (1.7%). No patients required new dialysis initiation within 30 days. Multivariable analysis did not identify baseline chronic kidney disease or IV contrast volume as independent predictors of CI-acute kidney injury. Conclusions: CI-acute kidney injury following pre-TAVI CT is low, even among patients with chronic kidney disease. Most cases were transient and did not require dialysis. Routine avoidance of CT due to chronic kidney disease may not be warranted.
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Interventricular septal thickness on cardiac computed tomography as a novel risk factor for conduction disturbances in patients undergoing transcatheter aortic valve replacement
We examined whether thickness of the basal muscular interventricular septum (IVS), as measured by pre-procedural computed tomography (CT), could be used to identify the risk of conduction disturbances following transcatheter aortic valve replacement (TAVR). The IVS is a pivotal region of the electrical conduction system of the heart where the atrioventricular conduction axis is located. Included were 78 patients with severe aortic stenosis who underwent CT imaging prior to TAVR. The thickness of muscular IVS was measured in the coronal view, in systolic phases, at 1, 2, 5, and 10 mm below the membranous septum (MS). The primary endpoint was a composite of conduction disturbance following TAVR. Conduction disturbances occurred in 24 out of 78 patients (30.8%). Those with conduction disturbances were significantly more likely to have a thinner IVS than those without conduction disturbances at every measured IVS level (2.98 ± 0.52 mm vs. 3.38 ± 0.52 mm, 4.10 ± 1.02 mm vs. 4.65 ± 0.78 mm, 6.11 ± 1.12 mm vs. 6.88 ± 1.03 mm, and 9.72 ± 1.95 mm vs. 10.70 ± 1.55 mm for 1, 2, 5 and 10 mm below MS, respectively, P < 0.05 for all). Multivariable logistic regression analysis showed that pre-procedural IVS thickness (P = 0.003). Pre-procedural CT assessment of basal IVS thickness is a novel predictive marker for the risk of conduction disturbances following TAVR. The IVS thickness potentially acts as an anatomical barrier protecting the underlying conduction system from mechanical compression during TAVR.
- 1 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Open AccessInterventricular septal thickness on cardiac computed tomography as a novel risk factor for conduction disturbances in patients undergoing transcatheter aortic valve replacement
We examined whether thickness of the basal muscular interventricular septum (IVS), as measured by pre-procedural computed tomography (CT), could be used to identify the risk of conduction disturbances following transcatheter aortic valve replacement (TAVR). The IVS is a pivotal region of the electrical conduction system of the heart where the atrioventricular conduction axis is located. Included were 78 patients with severe aortic stenosis who underwent CT imaging prior to TAVR. The thickness of muscular IVS was measured in the coronal view, in systolic phases, at 1, 2, 5, and 10 mm below the membranous septum (MS). The primary endpoint was a composite of conduction disturbance following TAVR. Conduction disturbances occurred in 24 out of 78 patients (30.8%). Those with conduction disturbances were significantly more likely to have a thinner IVS than those without conduction disturbances at every measured IVS level (2.98 ± 0.52 mm vs. 3.38 ± 0.52 mm, 4.10 ± 1.02 mm vs. 4.65 ± 0.78 mm, 6.11 ± 1.12 mm vs. 6.88 ± 1.03 mm, and 9.72 ± 1.95 mm vs. 10.70 ± 1.55 mm for 1, 2, 5 and 10 mm below MS, respectively, P < 0.05 for all). Multivariable logistic regression analysis showed that pre-procedural IVS thickness (P = 0.003). Pre-procedural CT assessment of basal IVS thickness is a novel predictive marker for the risk of conduction disturbances following TAVR. The IVS thickness potentially acts as an anatomical barrier protecting the underlying conduction system from mechanical compression during TAVR.
- 28 March 2024
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 18 (4) , 421-422
Characteristics of aortic root and vascular anatomy in bicuspid versus tricuspid aortic valve anatomy in patients referred for TAVR
- 28 March 2024
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 18 (4) , 421-422
Characteristics of aortic root and vascular anatomy in bicuspid versus tricuspid aortic valve anatomy in patients referred for TAVR
- Open Access
- 23 November 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (10) , 100726
Cardiac Magnetic Resonance Imaging in COVID-19 Vaccine-Associated Myocarditis Compared With Classical Myocarditis
- 23 November 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (10) , 100726
Open AccessCardiac Magnetic Resonance Imaging in COVID-19 Vaccine-Associated Myocarditis Compared With Classical Myocarditis
- Open Access
- 12 April 2023
- Published by Elsevier in SSRN Electronic Journal
GWAS and PRS-PheWAS Across Complex Phenotypes in the Human Phenotype Project
Background: Genome-Wide-Association Studies (GWAS) associate phenotypes and genetic variants across a study cohort. GWAS require large-scale cohorts with both phenotype and genetic sequencing data, limiting studied phenotypes. The Human Phenotype Project is a longitudinal study which has measured a wide range of clinical and biomolecular features from a self-assignment cohort over 5 years. The phenotypes collected are quantitative traits, providing higher resolution insights into the genetics of complex phenotypes.Methods: We present the results of GWAS and Polygenic Risk Score-Phenome-Wide Association Studies with 727 clinical phenotypes and 4,045 molecular features from the Human Phenotype Project. This includes clinical traits that have not been previously associated with genetics, including measures from continuous sleep monitoring, continuous glucose monitoring, liver ultrasound, hormonal status and fundus imaging.Findings: In GWAS of 8,681 individuals, we found significant associations between 106 clinical traits and 937 Single Nucleotide Polymorphisms. We found genes associated with both glycemic control and mental disorders, and we quantify the strength of genetic signals in serum metabolites. In Polygenic Risk Score Phenome-Wide-Association Studies for clinical traits, we found 16,047 significant associations.Conclusions: The entire set of findings, which we disseminate publicly, provides newfound resolution into the genetic architecture of complex human phenotypes. Our findings are available through an interactive online dashboard at https://zacharylevine.shinyapps.io/GWASDashboard/.FundingE.S. is supported by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation.
- 12 April 2023
- Published by Elsevier in SSRN Electronic Journal
Open AccessGWAS and PRS-PheWAS Across Complex Phenotypes in the Human Phenotype Project
Background: Genome-Wide-Association Studies (GWAS) associate phenotypes and genetic variants across a study cohort. GWAS require large-scale cohorts with both phenotype and genetic sequencing data, limiting studied phenotypes. The Human Phenotype Project is a longitudinal study which has measured a wide range of clinical and biomolecular features from a self-assignment cohort over 5 years. The phenotypes collected are quantitative traits, providing higher resolution insights into the genetics of complex phenotypes.Methods: We present the results of GWAS and Polygenic Risk Score-Phenome-Wide Association Studies with 727 clinical phenotypes and 4,045 molecular features from the Human Phenotype Project. This includes clinical traits that have not been previously associated with genetics, including measures from continuous sleep monitoring, continuous glucose monitoring, liver ultrasound, hormonal status and fundus imaging.Findings: In GWAS of 8,681 individuals, we found significant associations between 106 clinical traits and 937 Single Nucleotide Polymorphisms. We found genes associated with both glycemic control and mental disorders, and we quantify the strength of genetic signals in serum metabolites. In Polygenic Risk Score Phenome-Wide-Association Studies for clinical traits, we found 16,047 significant associations.Conclusions: The entire set of findings, which we disseminate publicly, provides newfound resolution into the genetic architecture of complex human phenotypes. Our findings are available through an interactive online dashboard at https://zacharylevine.shinyapps.io/GWASDashboard/.FundingE.S. is supported by the Minerva foundation with funding from the Federal German Ministry for Education and Research and by the European Research Council and the Israel Science Foundation.
- Open Access
- 4 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (7)
Noninvasive Hemodynamic Evaluation Following TAVI for Severe Aortic Stenosis
Background: Various hemodynamic changes occur following transcatheter aortic valve implantation (TAVI) that may impact therapeutic decisions. NICaS is a noninvasive bioimpedance monitoring system aimed at hemodynamic assessment. We used the NICaS system in patients with severe aortic stenosis (AS) to evaluate short‐term hemodynamic changes after TAVI. Methods and Results: We performed hemodynamic analysis using NICaS on 97 patients with severe AS who underwent TAVI using either self‐expandable (68%) or balloon‐expandable (32%) valves. Patients were more often women (54%) and had multiple comorbidities including hypertension (83%), coronary artery disease (46%), and diabetes (37%). NICaS was performed at several time points—before TAVI, soon after TAVI, at hospital discharge, and during follow‐up. Compared with baseline NICaS measurements, we observed a significant increase in systolic blood pressure and total peripheral resistance (systolic blood pressure 132±21 mm Hg at baseline versus 147±23 mm Hg after TAVI, P 5 , respectively, P P =0.037; stroke volume 61.4±14.8 versus 56.2±15.9 mL, P =0.001) in the immediate post‐TAVI period. At follow‐up (median 59 days [interquartile range, 40.5–91]) these measurements returned to values that were not different from the baseline. A significant improvement in echocardiography‐based left ventricular ejection fraction was observed from baseline to follow‐up (55.6%±11.6% to 59.4%±9.4%, P <0.001). Conclusions: Unique short‐term adaptive hemodynamic changes were observed using NICaS in patients with AS soon after TAVI. Noninvasive hemodynamic evaluation immediately following TAVI may contribute to the understanding of complex hemodynamic changes and merits favorable consideration.
- 4 April 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (7)
Open AccessNoninvasive Hemodynamic Evaluation Following TAVI for Severe Aortic Stenosis
Background: Various hemodynamic changes occur following transcatheter aortic valve implantation (TAVI) that may impact therapeutic decisions. NICaS is a noninvasive bioimpedance monitoring system aimed at hemodynamic assessment. We used the NICaS system in patients with severe aortic stenosis (AS) to evaluate short‐term hemodynamic changes after TAVI. Methods and Results: We performed hemodynamic analysis using NICaS on 97 patients with severe AS who underwent TAVI using either self‐expandable (68%) or balloon‐expandable (32%) valves. Patients were more often women (54%) and had multiple comorbidities including hypertension (83%), coronary artery disease (46%), and diabetes (37%). NICaS was performed at several time points—before TAVI, soon after TAVI, at hospital discharge, and during follow‐up. Compared with baseline NICaS measurements, we observed a significant increase in systolic blood pressure and total peripheral resistance (systolic blood pressure 132±21 mm Hg at baseline versus 147±23 mm Hg after TAVI, P 5 , respectively, P P =0.037; stroke volume 61.4±14.8 versus 56.2±15.9 mL, P =0.001) in the immediate post‐TAVI period. At follow‐up (median 59 days [interquartile range, 40.5–91]) these measurements returned to values that were not different from the baseline. A significant improvement in echocardiography‐based left ventricular ejection fraction was observed from baseline to follow‐up (55.6%±11.6% to 59.4%±9.4%, P <0.001). Conclusions: Unique short‐term adaptive hemodynamic changes were observed using NICaS in patients with AS soon after TAVI. Noninvasive hemodynamic evaluation immediately following TAVI may contribute to the understanding of complex hemodynamic changes and merits favorable consideration.
- Open Access
- 29 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 264
Albumin as a Prognostic Marker for Atrial Fibrillation Recurrence following Cryoballoon Ablation of Pulmonary Venous
Introduction: Atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI) ablation has clinical significance. Identifying risk factors for AF recurrence is important. We investigated serum albumin (SA) levels (g/dL) as a prognostic factor for the recurrence of AF following cryoballoon PVI ablation. Methods: We included patients who underwent cryoballoon PVI ablation at our institution between the years 2013 and 2018. The primary outcome was recurrence of AF during follow up. Results: Our cohort consisted of 126 patients (67% males, mean age 61.8 ± 10.0 years). The pattern of AF amongst the cohort was paroxysmal in 62.5%, persistent in 25.4%, and longstanding persistent in 6.3%. Those with lower SA levels had a mean AF duration significantly less than those with higher SA levels (2.81 years, 7.34 years, and 6.37 years for SA levels of p = 0.003). Patients with lower SA levels were significantly more likely to have had more previous cardioversions and a larger left atrial area and volume. The mean follow-up was 380 days, in which the AF recurrence rate was 20.6%. Patients with lower SA level had significantly more AF recurrences (47.4%, 16.7%, and 2.2% for SA levels of p < 0.001). Upon multivariate analysis, an SA level < 3.8 was associated with a higher risk of AF recurrence (OR = 5.422 95% CI 1.134; 25.910; p < 0.001). Conclusion: SA levels were found to be a strong independent marker for AF recurrence following PVI ablation.
- 29 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (1) , 264
Open AccessAlbumin as a Prognostic Marker for Atrial Fibrillation Recurrence following Cryoballoon Ablation of Pulmonary Venous
Introduction: Atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI) ablation has clinical significance. Identifying risk factors for AF recurrence is important. We investigated serum albumin (SA) levels (g/dL) as a prognostic factor for the recurrence of AF following cryoballoon PVI ablation. Methods: We included patients who underwent cryoballoon PVI ablation at our institution between the years 2013 and 2018. The primary outcome was recurrence of AF during follow up. Results: Our cohort consisted of 126 patients (67% males, mean age 61.8 ± 10.0 years). The pattern of AF amongst the cohort was paroxysmal in 62.5%, persistent in 25.4%, and longstanding persistent in 6.3%. Those with lower SA levels had a mean AF duration significantly less than those with higher SA levels (2.81 years, 7.34 years, and 6.37 years for SA levels of p = 0.003). Patients with lower SA levels were significantly more likely to have had more previous cardioversions and a larger left atrial area and volume. The mean follow-up was 380 days, in which the AF recurrence rate was 20.6%. Patients with lower SA level had significantly more AF recurrences (47.4%, 16.7%, and 2.2% for SA levels of p < 0.001). Upon multivariate analysis, an SA level < 3.8 was associated with a higher risk of AF recurrence (OR = 5.422 95% CI 1.134; 25.910; p < 0.001). Conclusion: SA levels were found to be a strong independent marker for AF recurrence following PVI ablation.